Final Recommendation Statement: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis - US Preventive Services Task Force

Final Recommendation Statement: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis - US Preventive Services Task Force

Final Recommendation Statement: PrEP for HIV Prevention

Final Recommendation Statement: Preexposure Prophylaxis for the Prevention of HIV Infection The U.S. Preventive Services Task Force released today a final recommendation statement on preexposure prophylaxis (PrEP) for the prevention of HIV infection. The Task Force found that clinicians should offer PrEP to persons at high risk for HIV. To view the recommendation and the evidence on which it is based, please go here. The final recommendation statement can also be found in the June 11 online issue of JAMA. The Final Recommendation Statement Is Available

FINAL RECOMMENDATION SUMMARY See the full statement

Population Recommendation Grade Persons at high risk of HIV acquisition The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition. A

WHY THIS MATTERS

"Clinicians have the opportunity to protect patients at high risk for HIV by offering PrEP,” says Task Force member Seth Landefeld, M.D. “To know which patients are good candidates for PrEP, clinicians need to ask all patients about their sexual history and injection drug use in an open and nonjudgmental way.”

WHERE WE ARE IN THE PROCESS

Draft Research Plan Final Research Plan Draft Recommendation / Draft Evidence Review  Final Recommendation / Evidence Summary